Genmab A/S announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab-lenalidomide showed an overall response rate of 98 percent and complete metabolic response of 87 percent in response evaluable patients with relapsed or refractory follicular lymphoma.
